Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Free access | 10.1172/JCI109543

Activation of Human Factor VII in Plasma and in Purified Systems: ROLES OF ACTIVATED FACTOR IX, KALLIKREIN, AND ACTIVATED FACTOR XII

Uri Seligsohn, Bjarne Østerud, Stephen F. Brown, John H. Griffin, and Samuel I. Rapaport

Department of Medicine, University of California, San Diego 92093

San Diego Veterans Administration Hospital, San Diego, California 92093

Department of Immunopathology, Scripps Clinic and Research Foundation, La Jolla, California 92093

Find articles by Seligsohn, U. in: PubMed | Google Scholar

Department of Medicine, University of California, San Diego 92093

San Diego Veterans Administration Hospital, San Diego, California 92093

Department of Immunopathology, Scripps Clinic and Research Foundation, La Jolla, California 92093

Find articles by Østerud, B. in: PubMed | Google Scholar

Department of Medicine, University of California, San Diego 92093

San Diego Veterans Administration Hospital, San Diego, California 92093

Department of Immunopathology, Scripps Clinic and Research Foundation, La Jolla, California 92093

Find articles by Brown, S. in: PubMed | Google Scholar

Department of Medicine, University of California, San Diego 92093

San Diego Veterans Administration Hospital, San Diego, California 92093

Department of Immunopathology, Scripps Clinic and Research Foundation, La Jolla, California 92093

Find articles by Griffin, J. in: PubMed | Google Scholar

Department of Medicine, University of California, San Diego 92093

San Diego Veterans Administration Hospital, San Diego, California 92093

Department of Immunopathology, Scripps Clinic and Research Foundation, La Jolla, California 92093

Find articles by Rapaport, S. in: PubMed | Google Scholar

Published October 1, 1979 - More info

Published in Volume 64, Issue 4 on October 1, 1979
J Clin Invest. 1979;64(4):1056–1065. https://doi.org/10.1172/JCI109543.
© 1979 The American Society for Clinical Investigation
Published October 1, 1979 - Version history
View PDF
Abstract

Factor VII can be activated, to a molecule giving shorter clotting times with tissue factor, by incubating plasma with kaolin or by clotting plasma. The mechanisms of activation differ. With kaolin, activated Factor XII (XIIa) was the apparent principal activator. Thus, Factor VII was not activated in Factor XII-deficient plasma, was partially activated in prekallikrein and high-molecular weight kininogen (HMW kininogen)-deficient plasmas, but was activated in other deficient plasmas. After clotting, activated Factor IX (IXa) was the apparent principal activator. Thus, Factor VII was not activated in Factor XII-,HMW kininogen-, XI-, and IX-deficient plasmas, but was activated in Factor VIII-, X-, and V-deficient plasmas. In further studies, purified small-fragment Factor XIIa (β-XIIa), kallikrein, and Factor IXa were added to partially purified Factor VII and to plasma. High concentrations of β-XIIa activated Factor VII in a purified system; much lower concentrations of β-XIIa activated Factor VII in normal plasma but not in prekallikrein or HWM kininogen-deficient plasmas. Kallikrein alone failed to activate partially purified Factor VII but did so when purified Factor IX was added. Kallikrein also activated Factor VII in normal, Factor XII-, and Factor IX-deficient plasmas. Purified Factor IXa activated partially purified Factor VII and had no additional indirect activating effect in the presence of plasma. These results demonstrate that both Factor XIIa and Factor IXa directly activate human Factor VII, whereas kallikrein, through generation of Factor XIIa and Factor IXa, functions as an indirect activator of Factor VII.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1056
page 1056
icon of scanned page 1057
page 1057
icon of scanned page 1058
page 1058
icon of scanned page 1059
page 1059
icon of scanned page 1060
page 1060
icon of scanned page 1061
page 1061
icon of scanned page 1062
page 1062
icon of scanned page 1063
page 1063
icon of scanned page 1064
page 1064
icon of scanned page 1065
page 1065
Version history
  • Version 1 (October 1, 1979): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts